ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today ...

Binding of miR-3036-5p to CYP18A1 can be prevented by an A-to-I RNA editing, thus elevating CYP18A1 expression, decreasing 20E titer, and finally regulating the wing dimorphism of offspring in aphid.